Does TALAZOPARIB Cause Second primary malignancy? 37 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Second primary malignancy have been filed in association with TALAZOPARIB (Talzenna). This represents 2.5% of all adverse event reports for TALAZOPARIB.
37
Reports of Second primary malignancy with TALAZOPARIB
2.5%
of all TALAZOPARIB reports
20
Deaths
11
Hospitalizations
How Dangerous Is Second primary malignancy From TALAZOPARIB?
Of the 37 reports, 20 (54.1%) resulted in death, 11 (29.7%) required hospitalization, and 8 (21.6%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TALAZOPARIB. However, 37 reports have been filed with the FAERS database.
What Other Side Effects Does TALAZOPARIB Cause?
Anaemia (219)
Neoplasm progression (169)
Death (142)
Off label use (78)
Thrombocytopenia (78)
Fatigue (77)
Platelet count decreased (68)
Haemoglobin decreased (65)
Febrile neutropenia (60)
Pancytopenia (60)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which TALAZOPARIB Alternatives Have Lower Second primary malignancy Risk?
TALAZOPARIB vs TALC
TALAZOPARIB vs TALIGLUCERASE ALFA
TALAZOPARIB vs TALIMOGENE LAHERPAREPVEC
TALAZOPARIB vs TALQUETAMAB
TALAZOPARIB vs TALQUETAMAB-TGVS